EU approves Novartis glaucoma combo

The European Commission has approved the eye drops to decrease elevated intraocular pressure (IOP) in adult patients with open-angle glaucoma or ocular hypertension, for which monotherapy provides insufficient IOP reduction.  

Simbrinza combines two well-established treatments for elevated IOP into one multi-dose bottle, "offering a simplified schedule compared to brinzolamide and brimonidine administered separately," according to Novartis, which, it is hoped, will help tackle current poor adherence rates to therapy.